UBXN2A and malignant colon neoplasm: As previously shown (Abdullah et al., 2015a), we first reconfirmed that VTD enhances expression of UBXN2A in a dose‐dependent manner in LoVo (Fig. S3B,C), a well‐differentiated colon cancer cell line.